Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
WALTHAM, Mass., March 02, 2017 -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter and year ended December 31, 2016, on March 16, 2017 before the market opens.
Histogenics’ management will host a conference call on Thursday, March 16, 2017 at 8:30 a.m. EDT. A question-and-answer session will follow Histogenics’ remarks. To participate on the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID “56826793” five to ten minutes before the start of the call.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the Histogenics website, www.histogenics.com. A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the presentation.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
